Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

0.64 

0.00 0.0%

as of May 18 '22

52 Week Range:

0.53 1.28


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin for chemotherapy-induced thrombopenia and immune thrombocytopenia; Ruisiyi, a non-steroidal aromatase inhibitor for breast cancer; EPIAO and SEPO recombinant human erythropoietins to treat anemia; Wanwei, a 5-HT3 receptor antagonist antiemetic drug for vomiting; and Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections. It also offers Inleusin, a recombinant human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up; Etanercept, a recombinant human type II tumor necrosis factor receptor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; BYETTA for the glycemic control in patients with type 2 diabetes; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, the company provides Mandi for the treatment of male-pattern alopecia and alopecia areata; Aiyishu to treat iron-deficiency anemia; Qiming Keli for retinopathy caused by type-2 diabetes; Disu, a bidirectional immunomodulator for the prevention and treatment of chronic bronchitis, cold, and asthma; Jiannipai, a recombinant humanized anti-CD25 monoclonal antibody injection to prevent acute rejection after renal transplantation; and Humulin, a recombinant insulin for diabetes. Further, it engages in the trading, project management and consultation, and technology services activities. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and INV. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 0.29
0.32
0.35
0.39
0.45
0.52
0.64
growth rate 10.3% 9.4% 11.4% 15.4% 15.6% 23.1%
Earnings BIT 278.70
343.32
603.28
820.09
1,098.57
1,222.38
1,128.78
1,341.26
growth rate 23.2% 75.7% 35.9% 34.0% 11.3% -7.7% 18.8%
Avg.PE 29.00
27.71
33.10
26.50
14.76
14.92
14.92
growth rate -4.5% 19.5% -19.9% -44.3% 1.1% 0.0%
ROA 8.69
7.36
12.65
11.78
8.07
7.55
9.26
6.80
5.15
8.95
growth rate -15.3% 31.1% -6.9% -31.5% -6.4% 22.7% -26.6% -24.3% 73.8%
ROE 9.16
7.87
31.29
16.05
11.73
13.44
15.95
10.68
8.23
14.41
growth rate -14.1% 99.4% -48.7% -26.9% 14.6% 18.7% -33.0% -22.9% 75.1%
ROIC 7.92
6.34
19.09
13.72
9.00
9.69
11.30
8.17
6.40
11.41
growth rate -20.0% 73.5% -28.1% -34.4% 7.7% 16.6% -27.7% -21.7% 78.3%
Cur. Ratio 15.54
14.25
0.75
3.58
1.96
2.40
2.68
2.85
4.60
5.49
growth rate -8.3% -77.1% 377.3% -45.3% 22.5% 11.7% 6.3% 61.4% 19.4%
Quick Ratio 14.19
13.17
0.44
2.65
1.63
2.17
2.36
2.39
3.88
4.42
growth rate -7.2% -81.7% 502.3% -38.5% 33.1% 8.8% 1.3% 62.3% 13.9%
Leverage 1.06
1.07
2.47
1.18
1.69
1.86
1.61
1.54
1.65
1.57
growth rate 0.9% 51.9% -52.2% 43.2% 10.1% -13.4% -4.4% 7.1% -4.9%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 235.25
399.75
665.38
822.91
1,668.39
2,046.83
1,302.63
1,268.27
growth rate 69.9% 66.5% 23.7% 102.7% 22.7% -36.4% -2.6%
Acct.Payable 7.03
25.64
34.44
58.79
274.57
112.92
149.76
203.29
growth rate 264.5% 34.4% 70.7% 367.0% -58.9% 32.6% 35.7%
Cur.Assets 926.09
942.63
2,762.97
2,240.73
5,276.22
4,437.53
4,596.18
6,679.91
growth rate 1.8% 193.1% -18.9% 135.5% -15.9% 3.6% 45.3%
Total Assets 1,268.33
2,306.44
6,630.43
11,038.80
13,752.97
13,839.66
14,809.31
17,678.20
growth rate 81.9% 187.5% 66.5% 24.6% 0.6% 7.0% 19.4%
Cash 267.53
107.61
1,299.40
677.60
2,398.62
1,792.61
2,082.85
3,090.84
growth rate -59.8% 1,107.5% -47.9% 254.0% -25.3% 16.2% 48.4%
Inventory 50.48
100.40
134.39
262.44
376.53
384.61
528.47
619.51
growth rate 98.9% 33.9% 95.3% 43.5% 2.2% 37.4% 17.2%
Cur.Liabilities 89.54
1,251.89
772.61
1,143.62
2,195.81
1,655.54
1,611.73
1,450.92
growth rate 1,298.1% -38.3% 48.0% 92.0% -24.6% -2.7% -10.0%
Liabilities 186.52
1,362.85
994.97
4,272.46
6,123.33
4,932.29
4,449.99
4,584.86
growth rate 630.7% -27.0% 329.4% 43.3% -19.5% -9.8% 3.0%
LT Debt 2,541.00
2,541.00
2,541.00
2,540.68
3,318.67
2,724.34
2,318.04
2,514.74
growth rate 0.0% 0.0% 0.0% 30.6% -17.9% -14.9% 8.5%
Equity 1,070.58
932.37
5,624.29
6,522.50
7,396.79
8,614.43
9,625.04
10,689.31
growth rate -12.9% 503.2% 16.0% 13.4% 16.5% 11.7% 11.1%
Common Shares 157.00
159.00
639.03
1,940.00
2,299.00
2,563.00
2,654.00
2,754.00
2,538.00
2,751.00
2,770.00
growth rate 1.3% 301.9% 203.6% 18.5% 11.5% 3.6% 3.8% -7.8% 8.4% 0.7%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 39.34
19.93
61.04
116.44
138.46
247.32
471.40
892.99
growth rate -49.3% 206.3% 90.8% 18.9% 78.6% 90.6% 89.4%
Cash Dividends 490.09
659.01
150.81
150.81
150.81
150.81
growth rate 34.5% -77.1% 0.0% 0.0% 0.0%
Cash From OA 217.25
386.59
455.27
1,004.32
1,074.10
1,150.25
1,887.38
1,344.56
growth rate 77.9% 17.8% 120.6% 7.0% 7.1% 64.1% -28.8%
FCF per Share 0.04
0.02
0.02
0.03
0.05
0.06
0.01
growth rate -50.0% 0.0% 50.0% 66.7% 20.0% -83.3%
Sale Purchase of Stock 2.13
4,132.89
4,132.89
growth rate 194,023.4% 0.0%
FCF 94.00
132.00
177.91
361.00
358.00
538.00
831.00
717.00
1,401.00
363.00
433.00
growth rate 40.4% 34.8% 102.9% -0.8% 50.3% 54.5% -13.7% 95.4% -74.1% 19.3%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 875.40
1,130.85
1,673.13
2,797.29
3,734.33
4,583.87
5,318.09
5,587.64
growth rate 29.2% 48.0% 67.2% 33.5% 22.8% 16.0% 5.1%
Op.Income 278.70
343.32
603.28
820.09
1,098.57
1,222.38
1,128.78
1,341.26
growth rate 23.2% 75.7% 35.9% 34.0% 11.3% -7.7% 18.8%
IBT 208.71
360.18
587.86
850.07
1,102.02
1,495.51
1,223.01
979.13
growth rate 72.6% 63.2% 44.6% 29.6% 35.7% -18.2% -19.9%
Net Income 95.89
291.73
526.28
712.56
935.39
1,277.17
973.72
835.79
growth rate 204.2% 80.4% 35.4% 31.3% 36.5% -23.8% -14.2%
EPS 0.69
0.64
0.15
0.23
0.28
0.36
0.49
0.38
0.33
0.62
growth rate -7.3% -51.6% 53.3% 21.7% 28.6% 36.1% -22.5% -13.2% 87.9%
Gross Profit 792.22
1,043.37
1,431.22
2,395.02
3,058.10
3,706.61
4,392.74
4,524.73
growth rate 31.7% 37.2% 67.3% 27.7% 21.2% 18.5% 3.0%
R&D 362.71
362.71
362.71
526.57
590.34
growth rate 0.0% 0.0% 45.2% 12.1%

Quarterly Statements

Item Name Jun '20 Sep '20 Dec '20 Mar '21 Jun '21
Earnings BIT 398.05
272.58
272.58
466.34
466.34
growth rate -31.5% 0.0% 71.1% 0.0%
Balance Sheet Jun '20 Sep '20 Dec '20 Mar '21 Jun '21
Acct.Receivable 1,182.39
1,268.27
1,268.27
1,224.10
1,224.10
growth rate 7.3% 0.0% -3.5% 0.0%
Acct.Payable 166.20
203.29
203.29
214.95
214.95
growth rate 22.3% 0.0% 5.7% 0.0%
Cur.Assets 6,871.76
6,679.91
6,679.91
7,401.70
7,401.70
growth rate -2.8% 0.0% 10.8% 0.0%
Total Assets 17,603.43
17,678.20
17,678.20
18,541.25
18,541.25
growth rate 0.4% 0.0% 4.9% 0.0%
Cash 3,793.11
3,090.84
3,090.84
2,919.68
2,919.68
growth rate -18.5% 0.0% -5.5% 0.0%
Inventory 569.88
619.51
619.51
681.50
681.50
growth rate 8.7% 0.0% 10.0% 0.0%
Cur.Liabilities 1,651.35
1,450.92
1,450.92
1,334.97
1,334.97
growth rate -12.1% 0.0% -8.0% 0.0%
Liabilities 6,109.28
4,584.86
4,584.86
4,412.59
4,412.59
growth rate -25.0% 0.0% -3.8% 0.0%
LT Debt 3,920.38
2,514.74
2,514.74
2,452.38
2,452.38
growth rate -35.9% 0.0% -2.5% 0.0%
Equity 10,676.62
10,689.31
10,689.31
11,732.52
11,732.52
growth rate 0.1% 0.0% 9.8% 0.0%
Common Shares 0.16
0.16
0.16
0.16
0.16
growth rate 0.0% 0.0% 0.7% 0.0%
Cash Flow Statement Jun '20 Sep '20 Dec '20 Mar '21 Jun '21
Capital Expenditures 154.93
291.56
291.56
234.24
234.24
growth rate 88.2% 0.0% -19.7% 0.0%
Cash Dividends
growth rate
Cash From OA 354.12
318.16
318.16
405.75
405.75
growth rate -10.2% 0.0% 27.5% 0.0%
FCF 199.18
26.60
26.60
171.51
171.51
growth rate -86.6% 0.0% 544.7% 0.0%
Income Statement Jun '20 Sep '20 Dec '20 Mar '21 Jun '21
Sales 1,347.59
1,446.23
1,446.23
1,553.57
1,553.57
growth rate 7.3% 0.0% 7.4% 0.0%
Op.Income 398.05
272.58
272.58
466.34
466.34
growth rate -31.5% 0.0% 71.1% 0.0%
IBT 409.29
80.28
80.28
512.93
512.93
growth rate -80.4% 0.0% 539.0% 0.0%
Net Income 351.24
66.65
66.65
449.45
449.45
growth rate -81.0% 0.0% 574.3% 0.0%
Gross Profit 1,108.54
1,153.82
1,153.82
1,293.57
1,293.57
growth rate 4.1% 0.0% 12.1% 0.0%
R&D 127.17
168.00
168.00
172.43
172.43
growth rate 32.1% 0.0% 2.6% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (69.43)

YOY Growth Grade:

C (64.15)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 14.92 10.32
EPS / Growth 0.06

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 21.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 21.6% 21.6% 21.6%
Future PE 0.01 9.95 19.40
Future EPS 0.44 0.44 0.44
Value Price
MOS %
0.00
-99.8%
1.08
68.8%
2.11
229.1%
MOS Price 0.00 0.54 1.05
IRT 5.30 5.30 5.30

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.